Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells

Urology

Volumn 75, Issue 4, 2010, Pages 793-798

  Goktas, Serdar ^a   Baran, Yusuf ^a,b   Ural, Ali U ^a   Yazici, Sertac ^a,c   Aydur, Emin ^a   Basal, Seref ^a   Avcu, Ferit ^a   Pekel, Aysel ^a   Dirican, Bahar ^a   Beyzadeoglu, Murat ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; BORTEZOMIB; CASPASE 3; LIPOCORTIN 5; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN DU145; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGENS; BORONIC ACIDS; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 77950300115     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.07.1215     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Catalona W.J., Ramos C.G., and Carvalhal G.F. Contemporary results of anatomical prostatectomy. CA Cancer J Clin 49 (1999) 282-296
3. Zelefsky M.J., Marion C., Fuks Z., et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beamradiotherapy. J Urol 170 (2003) 1828-1832
4. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 281 (1999) 1591-1597
5. Goktas S., and Crawford D. Optimal hormone therapy for advanced prostatic carcinoma. Semin Oncol 26 (1999) 162-173
6. Michels J., Montemurro T., Murray N., et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?. Cancer 106 (2006) 1041-1046
7. Tan W.W. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control 13 (2006) 194-198
8. Lashinger L.M., Zhu K., Williams S.A., et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65 (2005) 4902-4908
9. An J., Sun Y., Adams J., et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis inducing ligand in prostate cancer. Clin Cancer Res 9 (2003) 4537-4545
10. Frankel A., Man S., Elliott P., et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6 (2000) 3719-3728
11. Ikezoe T., Yang Y., Saito T., et al. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 95 (2004) 271-275
12. Cao W., Shiverick K.T., Namiki K., et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol 26 (2008) 509-516
13. Dreicer R., Petrylak D., Agus D., et al. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13 (2007) 1208-1215
14. Baran Y., Gunduz U., and Ural A.U. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol 28 (2006) 163-165
15. Ogretmen B., Schady D., Usta J., et al. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 276 (2001) 24901-24910
16. Baran Y., Salas A., Senkal C.E., et al. Alterations of human longevity assurance gene 1 (LASS1)/sphingosine kinase-1-dependent ceramide generation and metabolism involve in the regulation of imatinib-induced apoptosis and resistance in k562 human chronic myeloid leukemia (cml) cells. J Biol Chem 282 (2007) 10922-10934
17. Adams J., Palombella V.J., and Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18 (2000) 109-121
18. Herrmann J.L., Briones Jr. F., Brisbay S., et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17 (1998) 2889-2899
19. Goldberg A.L., Stein R., and Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2 (1995) 503-508
20. Papandreou C.N., and Logothetis C.J. Bortezomib as a potential treatment of prostate cancer. Cancer Res 64 (2004) 5036-5043
21. Feinman R., Aris V.M., and Vergano S. Transcriptional gene expression profiles in drug-sensitive and Bcl-2-resistant myeloma cells in response to dexamethasone, arsenic trioxide, and PS-341. Blood 98 (2001) 368a
22. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
23. Huang S., Pettaway C.A., Uehara H., et al. Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
24. Zong W.X., Edelstein L.C., Chen C., et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNF-α-induced apoptosis. Genes Dev 13 (1999) 382-387
25. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 suppl 1 (2003) 3-9
26. Williams S., Pettaway C., Song R., et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2 (2003) 835-843
27. Russo S.M., Tepper J.E., Baldwin Jr. A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
28. Pervan M., Pajonk F., Sun J.R., et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 24 (2001) 481-485
29. Rosser C.J., Reyes A.O., Vakar-Lopez F., et al. Bcl-2 is signiffcantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 56 (2003) 1-6
30. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2108-2121
31. Hainsworth J.D., Meluch A.A., Spigel D.R., et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer 5 (2007) 278-283